en · de · es · fr · pt
liraglutide-notes.peptides1004.com › Faq › Melanocortin Receptor Signaling Mechanism — 2026 Update

Melanocortin Receptor Signaling Mechanism — 2026 Update

By Editorial Desk · published 2025-12-07 · last reviewed 2026-01-29 · Faq

A practical reference on Cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.

Melanocortin Receptor Signaling Mechanism

Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.

From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.

PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.

Chemical Identity of Bremelanotide

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

Pt-141 at a glance

PropertyValueNotes
Primary targetMelanocortin receptorsMainly the MC4R subtype
Route of administrationInjectionTypically subcutaneous
Time to peakAbout 60 minutesAfter subcutaneous dosing
Elimination half-lifeRoughly 2 to 3 hoursValues vary across reports
Metabolic pathwayPeptidase hydrolysisCleared by the kidneys

Receptor Pharmacology And Signalling

The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.

Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.

Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.

Related pages on this site

Analytical Characterisation and Storage Practice

Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.

The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.

Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.

Background and Receptor Pharmacology

Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.

Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.

Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.

Reference notes

tetramer A molecular aggregate consisting of four subunits. The term is often used to refer to protein complexes composed of four proteins, e.g. haemoglobin, or to individual proteins composed of four polypeptides. Compare monomer, dimer, and trimer.

=== 2023: French Open semifinals, Hamburg title === Zverev returned to the tour for the first time since his ankle injury by participating at the inaugural United Cup where he lost in straight sets to Jiří Lehečka and Taylor Fritz. Seeded 12th at the Australian Open, he won his first match since June 2022 by beating lucky loser, Juan Pablo Varillas, in the first round in five sets. He was defeated in the second round by American and lucky loser, Michael Mmoh, in four sets. After the Australian Open, Zverev represented Germany in the Davis Cup tie against Switzerland. He won his first match over Stan Wawrinka. He lost his second match to Marc-Andrea Hüsler. Switzerland ended up winning the tie over Germany 3–2. Seeded eighth at the Rotterdam Open, he was eliminated from the tournament in the second round by Dutch wildcard, Tallon Griekspoor, in three sets. Seeded fourth at the Qatar ExxonMobil Open, he fell in the second round to wildcard, former world No. 1, two-time champion, and eventual finalist, Andy Murray. In March, he played at the Dubai Championships. Seeded seventh, he reached the semifinals where he lost to second seed, defending champion, and eventual finalist, Andrey Rublev. Zverev began his early U.S. hard court campaign at the Indian Wells Masters. Seeded 12th, he reached the fourth round but lost to fifth seed, world No. 6, and eventual finalist, Daniil Medvedev, in three close sets. Seeded 13th at the Miami Open, he was beaten in the second round by wildcard Taro Daniel. Zverev began his clay-court season at the Monte-Carlo Masters.

The Terek Cossack Host was created in 1577 by free Cossacks resettling from the Volga to the Terek River. Local Terek Cossacks joined this host later. In 1792, the host was included in the Caucasus Line Cossack Host, from which it separated again in 1860, with Vladikavkaz as its capital. In 1916, the population of the host was 255,000, within an area of 1.9 million desyatinas.

Sources: en.wikipedia.org

Notes from published material

The plasmon resonance displayed by nanoparticles, gold particles are most often used as an example, can be altered using the interfacial layer. When either anionic or cationic ligands bound to a nanoparticle made of gold for example are increased in length, the wavelength of the plasmon resonance will shift to red. An example of another effect, that has recently been observed by Amendola et al. on small gold nanoparticles, of 10 nm or less, is that dense monolayers that consist of certain specific short chain ligands tend to dampen the surface plasmon resonance effects. Plasmon resonance can be used to analyze the surfactants of the nanoparticle. This principle is based on the so-called Fröhlich condition which states that the refractive index of the surrounding medium of a nanoparticle can be used to tune or alter the frequency of the surface plasmon resonance. The equation that relates both properties is as follows:

A 2015 PHE report found that high levels of formaldehyde only occurred in overheated "dry-puffing", and that "dry puffs are aversive and are avoided rather than inhaled", and "At normal settings, there was no or negligible formaldehyde release." A 2018 study confirmed e-cigarettes can emit formaldehyde at high levels more than 5 times higher than what is reported for cigarette smoke) at moderate temperatures and under conditions that have been reported to be non-averse to users. But e-cigarette users may "learn" to overcome the unpleasant taste due to elevated aldehyde formation, when the nicotine craving is high enough. High voltage e-cigarettes are capable of producing large amounts of carbonyls. Reduced voltage (3.0 V) e-cigarettes had e-cigarette aerosol levels of formaldehyde and acetaldehyde roughly 13 and 807-fold less than with cigarette smoke.

double helix The shape most commonly assumed by double-stranded nucleic acid molecules, resembling a ladder that has been twisted upon its long axis, with the rungs of the ladder consisting of paired nucleobases. This secondary structure is the most energetically stable conformation of the double-stranded forms of both DNA and RNA under most naturally occurring conditions, arising as a consequence of the primary structure of the phosphodiester backbone and the stacking of the nucleotides bonded to it. In B-DNA, the most common DNA variant found in nature, the double helix has a right-handed twist with about 10 base pairs per full turn, and the molecular geometry results in an alternating pattern of "grooves" of differing widths (a major groove and a minor groove) between the parallel backbones.

Solute carrier family 22 member 1 (organic cation transporter isoform 1) is an efflux pump and expressed predominantly in hepatic cells, where morphine is metabolised by UGT2B7, loss of function mutations increase the area under the curve (AUC) by 1.5 (one allele) to 1.7 times (no active allele). μ-opioid receptor: homozygous G/G carriers of the OPRM1 118 A>G variant (rs1799971) are shown to require more morphine. P‐glycoprotein is expressed in the blood-brain barrier, small intestine, liver and kidneys and therefore affects the pharmacokinetics. The 3435T allele of the SNP rs1045642 reduces mRNA stability and results in lower efflux function, and is associated with better response to morphine. UDP-Glucuronosyltransferase-2B7: The most common polymorphism is 802 C>T (rs7439366, UGT2B7*2), which depending on the substrate increases or decreases function. The T allele is associated with lower glucoronidation of morphine and extended analgesia.

Sources: en.wikipedia.org

Further detail

And while many studies have discussed and illustrated the immunosuppressive effects of CGB on T-cell proliferation, others have shown a contradictory trophic effect, further deepening the notion of an immunosuppressive pregnancy environment brought on by CGB. CGB encourages trophoblast invasion and interstitial theca cell proliferation through the overmodulation of extracellular-regulated kinase (ERK) and AKT signals, and the instigation of leptin production by CGB requires a dialogue between cAMP and p38 signaling pathways in the syncytiotrophoblast. It has also been shown that CGB has a positive impact on the proliferation of CD4+25+ T cells and that it attracts these cells to the endometrium in early pregnancy. Immune cells located at the implantation site actively contribute to embryo implantation. And so, through the modulation of inflammatory-promoting Th1 cells and anti-inflammatory Th2 cells, CGB plays a critically important role in the successful implantation of the embryo to the endometrial wall.

== Deaths == 28 March – Paul O'Grady, comedian, actor and drag queen (born 1955) 22 April – Len Goodman, ballroom dancer and television personality (born 1944) 26 November – Terry Venables, football player and manager (born 1943)

1913: Canadian physician and chemist Maud Menten co-authored a paper on enzyme kinetics, leading to the development of the Michaelis–Menten kinetics equation. 1914–1918: During World War I, a team of seven British women chemists conducted pioneering research on chemical antidotes and weaponized gases. The project leader, Martha Annie Whiteley, was awarded the Order of the British Empire for her wartime contributions. 1914-1918: English botanist and mycologist Helen Gwynne-Vaughan was the first woman to be awarded a military DBE for her wartime service in January 1918. She served as Commandant of the Women's Royal Air Force (WRAF) from September 1918 until December 1919. 1914: British-born mycologist Ethel Doidge became the first woman in South Africa to receive a doctorate in any subject, receiving her doctorate of science degree from the University of the Good Hope. She wrote her thesis on "A bacterial disease of mango". 1916: Canadian horticulturist Isabella Preston became the first female professional plant hybridist in Canada, producing the George C. Creelman trumpet lily. Her lily later received an Award of Merit from the Royal Horticultural Society. 1916: Chika Kuroda became the first Japanese woman to earn a bachelor of science degree, studying chemistry at the Tohoku Imperial University. After graduation, she was subsequently appointed an assistant professor at the university. 1917: American zoologist Mary J. Rathbun received her PhD from the George Washington University.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor system does PT-141 act on?

It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.

How does its action differ from melanotan II?

It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.

What delivery routes are used for this peptide?

Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.

What class of compound is PT-141?

It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.

Network